These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 12527336)

  • 1. Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes.
    Hameg A; Bayle F; Nuss P; Dupuis P; Garay RP; Dib M
    Biochem Pharmacol; 2003 Feb; 65(3):435-40. PubMed ID: 12527336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes.
    Benyamina A; Arbus C; Nuss P; Garay RP; Neliat G; Hameg A
    Eur J Pharmacol; 2008 Jan; 578(2-3):142-7. PubMed ID: 17936750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders.
    Kalkman HO; Subramanian N; Hoyer D
    Neuropsychopharmacology; 2001 Dec; 25(6):904-14. PubMed ID: 11750183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity.
    Alvarez-Guerra M; d'Alché-Birée F; Wolf WA; Vargas F; Dib M; Garay RP
    Psychopharmacology (Berl); 2000 Jan; 147(4):412-7. PubMed ID: 10672635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active cyamemazine metabolites in patients treated with cyamemazine (Tercian®): influence on cerebral dopamine D2 and serotonin 5-HT (2A) receptor occupancy as measured by positron emission tomography (PET).
    Hodé Y; Benyamina A; Arbus C; Reimold M
    Psychopharmacology (Berl); 2011 Oct; 217(3):315-21. PubMed ID: 21479533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
    Millan MJ; Maiofiss L; Cussac D; Audinot V; Boutin JA; Newman-Tancredi A
    J Pharmacol Exp Ther; 2002 Nov; 303(2):791-804. PubMed ID: 12388666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian).
    Hodé Y; Reimold M; Demazières A; Reischl G; Bayle F; Nuss P; Hameg A; Dib M; Macher JP
    Psychopharmacology (Berl); 2005 Jul; 180(2):377-84. PubMed ID: 15948013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.
    Millan MJ; Newman-Tancredi A; Audinot V; Cussac D; Lejeune F; Nicolas JP; Cogé F; Galizzi JP; Boutin JA; Rivet JM; Dekeyne A; Gobert A
    Synapse; 2000 Feb; 35(2):79-95. PubMed ID: 10611634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential role of cortical 5-HT(2A) receptors in the anxiolytic action of cyamemazine in benzodiazepine withdrawal.
    Benyamina A; Naassila M; Bourin M
    Psychiatry Res; 2012 Jul; 198(2):307-12. PubMed ID: 22421069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.
    Shapiro DA; Renock S; Arrington E; Chiodo LA; Liu LX; Sibley DR; Roth BL; Mailman R
    Neuropsychopharmacology; 2003 Aug; 28(8):1400-11. PubMed ID: 12784105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.
    Dekeyne A; Mannoury la Cour C; Gobert A; Brocco M; Lejeune F; Serres F; Sharp T; Daszuta A; Soumier A; Papp M; Rivet JM; Flik G; Cremers TI; Muller O; Lavielle G; Millan MJ
    Psychopharmacology (Berl); 2008 Sep; 199(4):549-68. PubMed ID: 18523738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of serotonin and dopamine receptor binding in antipsychotic efficacy.
    Richtand NM; Welge JA; Logue AD; Keck PE; Strakowski SM; McNamara RK
    Prog Brain Res; 2008; 172():155-75. PubMed ID: 18772032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
    Millan MJ; Mannoury la Cour C; Chanrion B; Dupuis DS; Di Cara B; Audinot V; Cussac D; Newman-Tancredi A; Kamal M; Boutin JA; Jockers R; Marin P; Bockaert J; Muller O; Dekeyne A; Lavielle G
    J Pharmacol Exp Ther; 2012 Mar; 340(3):750-64. PubMed ID: 22178752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine.
    Peinado J; Hameg A; Garay RP; Bayle F; Nuss P; Dib M
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Feb; 367(2):134-9. PubMed ID: 12595954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.
    Ishibashi T; Horisawa T; Tokuda K; Ishiyama T; Ogasa M; Tagashira R; Matsumoto K; Nishikawa H; Ueda Y; Toma S; Oki H; Tanno N; Saji I; Ito A; Ohno Y; Nakamura M
    J Pharmacol Exp Ther; 2010 Jul; 334(1):171-81. PubMed ID: 20404009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice.
    Bourin M; Nic Dhonnchadha BA ; Claude Colombel M; Dib M; Hascoët M
    Behav Brain Res; 2001 Sep; 124(1):87-95. PubMed ID: 11423169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-HT2A receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle.
    Alvarez-Guerra M; Hameg A; Bayle F; Dib M; Garay RP
    Eur J Pharmacol; 2002 Nov; 454(2-3):235-9. PubMed ID: 12421652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT)(1B) and h5-HT(1D) receptors.
    Audinot V; Newman-Tancredi A; Cussac D; Millan MJ
    Neuropsychopharmacology; 2001 Sep; 25(3):410-22. PubMed ID: 11522469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome.
    Bourin M; Dailly E; Hascöet M
    CNS Drug Rev; 2004; 10(3):219-29. PubMed ID: 15492772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.
    Stark AD; Jordan S; Allers KA; Bertekap RL; Chen R; Mistry Kannan T; Molski TF; Yocca FD; Sharp T; Kikuchi T; Burris KD
    Psychopharmacology (Berl); 2007 Feb; 190(3):373-82. PubMed ID: 17242925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.